Cho, Eun-Yeong
Cho, Jung-Eun
Jang, Seung Hun
Hwang, Ki-Eun
Article History
Accepted: 12 July 2023
First Online: 31 August 2023
Declarations
:
: This study (204674) was funded by GSK.
: Eun-Yeong Cho was an employee and shareholder, and Jung-Eun Cho is an employee, of GSK. Seung-Hun Jang and Ki-Eun Hwang declare no relevant conflict of interests. Trademarks are owned by or licensed to their respective owners (GSK [RELVAR ELLIPTA]).
: Not applicable.
: Informed consent was obtained from all individual participants included in the study.
: Information on GSK’s data sharing commitments can be found at ExternalRef removed.
: This study adhered to the guidelines for local legislation and the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of each study centre including Hallym University Sacred Heart Hospital (IRB approval number: 2016-S033).
: Not applicable.
: All authors contributed to the writing of the manuscript, including reviewing and editing, and all provided their approval for the final version. Eun-Yeong Cho: Conceptualization, Methodology, Writing (original draft preparation), Supervision; Jung-Eun Cho: Conceptualization, Methodology, Writing (original draft preparation), Formal analysis; Seung Hun Jang: Investigation (including clinical data collection); Ki-Eun Hwang: Investigation (including clinical data collection).